Designing a tool allowing for a standardized assessment of resistance to drug diversion

Bibliography

• Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83(Suppl 1):S4-7
   PubMed Web of Science ®Google Scholar
• Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23(8):648-60
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm 2013;39(5):611-24
   PubMed Web of Science ®Google Scholar
• FDA dgfi. Assessment of Abuse Potential of Drugs. 2010. Available from: http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650pdf
   Google Scholar
• Courty P. High dosage buprenorphine and injection practices. A study of 303 patients. Ann Med Interne (Paris) 2003;154(Spec No 1 ):S35-45
   PubMedGoogle Scholar
• Victorri-Vigneau C, Dailly E, Veyrac G, et al. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007;64(2):198-209
   PubMed Web of Science ®Google Scholar
• Schuster CR, Henningfield J. Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend 2003;70(3 Suppl):S1-4
   PubMed Web of Science ®Google Scholar
• Sellers EM, Schuller R, Romach MK, et al. Relative abuse potential of opioid formulations in Canada: a structured field study. J Opioid Manag 2006;2(4):219-27
   PubMedGoogle Scholar
• Tharp AM, Winecker RE, Winston DC. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol 2004;25(2):178-81
   PubMed Web of Science ®Google Scholar
• Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend 2008;92(1-3):267-76
   PubMed Web of Science ®Google Scholar
• Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 1995;29(10):969-71
   PubMed Web of Science ®Google Scholar
• Correas Lauffer J, Braquehais Conesa D, Barbudo Del Cura E, et al. Abuse, tolerance and dependence of zolpidem: three case reports. Actas Esp Psiquiatr 2002;30(4):259-62
   PubMed Web of Science ®Google Scholar
• Lourenco LM, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv 2013;10(2):229-40
   PubMed Web of Science ®Google Scholar
• Gaulier JM, Fonteau F, Jouanel E, et al. Rape drugs: pharmalogical and analytical aspects. Ann Biol Clin (Paris) 2004;62(5):529-38
   PubMed Web of Science ®Google Scholar
• Thirion X, Barrau K, Micallef J, et al. [Maintenance treatment for opioid dependence in care centers: the OPPIDUM program of the Evaluation and Information Centers for Drug Addiction]. Ann Med Interne (Paris) 2000;151(Suppl A):A10-17
   PubMedGoogle Scholar
• Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006;83(Suppl 1):S8-14
   PubMedGoogle Scholar
• Hamed E, Moe D. Development of tamper deterrent formulations: state of the pharmaceutical industry. Curr Drug Abuse Rev 2010;3(3):139-46
   PubMedGoogle Scholar
• Mansbach RS, Moore RA Jr. Formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend 2006;83(Suppl 1):S15-22
   PubMedGoogle Scholar
• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010;70(13):1657-75
   PubMed Web of Science ®Google Scholar
• Sapienza FL. Abuse deterrent formulations and the Controlled Substances Act (CSA). Drug Alcohol Depend 2006;83(Suppl 1):S23-30
   PubMed Web of Science ®Google Scholar
• Seed SM, Dunican KC, Lynch AM, et al. An update in options for the treatment of pain: a review of new opioid formulations. Hosp Pract (1995) 2012;40(1):166-75
   Google Scholar
• Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc 2012;87(7):683-94
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Jones JD, Manubay JM, et al. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin(R) (non-TRF) in prescription opioid abusers. Addiction 2013;108(6):1095-106
   PubMed Web of Science ®Google Scholar
• Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009;10(Suppl 2):S124-33
   PubMed Web of Science ®Google Scholar
• Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 2009;18(3):255-63
   PubMed Web of Science ®Google Scholar
• Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain 2010;11(7):602-11
   PubMed Web of Science ®Google Scholar
• Wick JY. Drug-abuse deterrent formulations. Consult Pharm 2009;24(5):356-62; 365
   PubMedGoogle Scholar
• Chai LY, Khare CB, Chua A, et al. Buprenorphine diversion: a possible reason for increased incidence of infective endocarditis among injection drug users? The Singapore experience. Clin Infect Dis 2008;46(6):953-5; author reply 5-6
   PubMed Web of Science ®Google Scholar
• Chevalley AE, Besson J, Croquette-Krokar M, et al. Prevalence of methadone injection in three Swiss cities. Presse Med 2005;34(11):776-80
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Johnson RE. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006;83(Suppl 1):S40-7
   PubMedGoogle Scholar
• Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year. J Opioid Manag 2012;8(2):115-25
   PubMedGoogle Scholar
• Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010;105(4):709-18
   PubMed Web of Science ®Google Scholar
• Ruan X. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond. Expert Opin Pharmacother 2011;12(7):999-1001
   PubMed Web of Science ®Google Scholar
• Baumevieille M, Miremont G, Haramburu F, et al. [The French system of evaluation of dependence: establishment in a legal system]. Therapie 2001;56(1):15-22
   PubMed Web of Science ®Google Scholar
• Micaleff J, Jolliet P, Victorri-Vigneau C, et al. First meeting of the French CEIP (centres d'evaluation et d'information sur la pharmacodependance). Assessment of the abuse and pharmacodependence potential during drug development. Therapie 2008;63(1):55-65
   PubMed Web of Science ®Google Scholar
• Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 2003;70(Suppl 3):S13-40
   PubMed Web of Science ®Google Scholar
• Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs 2012;72(13):1713-23
   PubMed Web of Science ®Google Scholar
• Butler SF, Black R, Grimes Serrano JM, et al. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med 2010;11(1):81-91
   PubMed Web of Science ®Google Scholar
• Butler SF, Fernandez KC, Chang A, et al. Measuring attractiveness for abuse of prescription opioids. Pain Med 2010;11(1):67-80
   PubMed Web of Science ®Google Scholar
• Coleman JJ, Bensinger PB, Gold MS, et al. Can drug design inhibit abuse? J Psychoactive Drugs 2005;37(4):343-62
   PubMed Web of Science ®Google Scholar
• Grudzinskas C, Balster RL, Gorodetzky CW, et al. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend 2006;83(Suppl 1):S77-82
   PubMedGoogle Scholar
• Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008;10(1):11-18
   PubMedGoogle Scholar
• McColl S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 2006;83(Suppl 1):S52-62
   PubMedGoogle Scholar
• McCormick CG. Regulatory challenges for new formulations of controlled substances in today's environment. Drug Alcohol Depend 2006;83(Suppl 1):S63-7
   PubMedGoogle Scholar
• Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007;27(5):459-67
   PubMed Web of Science ®Google Scholar
• Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010;24(10):805-10
   PubMed Web of Science ®Google Scholar
• Wright CT, Kramer ED, Zalman MA, et al. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend 2006;83(Suppl 1):S68-76
   PubMedGoogle Scholar
• Canada S. Clinical Assessment of Abuse Liability for Drugs with Central Nervous System Activity 2007. Available from: http://wwwhc-scgcca/dhp-mps/prodpharma/applic-demande/guide-ld/abus/abuse_liability_abusif_usage_clin-fraphp
   Google Scholar
• Licata SC, Mashhoon Y, Maclean RR, et al. Modest abuse-related subjective effects of zolpidem in drug-naive volunteers. Behav Pharmacol 2011;22(2):160-6
   PubMed Web of Science ®Google Scholar
• Thirion X, Micallef J, Barrau K, et al. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Eur Addict Res 2001;7(1):32-6
   PubMed Web of Science ®Google Scholar
• Thirion X, Micallef J, Guet F, et al. [Dependence on psychotropic drugs and substitution treatment: recent trends. The OPPIDUM study of the Centers for Evaluation and Information on Drug Dependence (CEIP), October 1997]. Therapie 1999;54(2):243-9
   PubMedGoogle Scholar
• San Marco JL, Jouglard J, Thirion X, et al. [Observation of illicit or misused psychotropic drugs (O.P.P.I.D.U.M.): five years of surveillance of products consumed by drug addicts at Marseille]. Therapie 1996;51(5):586-98
   PubMedGoogle Scholar
• Pauly V, Frauger E, Rouby F, et al. Analysis of addictive behaviours among new prisoners in France using the OPPIDUM program. Encephale 2010;36(2):122-31
   PubMed Web of Science ®Google Scholar
• Moracchini C, Frauger E, Pauly V, et al. Harm reduction centers (“CAARUD”): privileged places for warning signal detection in addictovigilance. Therapie 2012;67(5):437-45
   PubMed Web of Science ®Google Scholar
• Djezzar S, Questel F, Burin E, et al. Chemical submission: results of 4-year French inquiry. Int J Legal Med 2009;123(3):213-19
   PubMed Web of Science ®Google Scholar
• ANSM. Assesment tools 2009. Available from: http://ansmsantefr/Activites/Pharmacodependance-Addictovigilance/Outils-de-surveillance-et-d-evaluation-Resultats-d-enquetes/(offset)/3
   Google Scholar
• Eiden C, Leglise Y, Bertomeu L, et al. New formulation of methadone for opioid dependence in France: acceptability and diversion/misuse liability. Therapie 2013;68(2):107-11
   PubMed Web of Science ®Google Scholar
• FDA dgfi. Abuse-Deterrent Opioids, Evaluation and Labeling 2013. Available from: http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
   Google Scholar
• Katz NP, Buse DC, Budman SH, et al. Development and preliminary experience with an ease of extractability rating system for prescription opioids. Drug Dev Ind Pharm 2006;32(6):727-46
   PubMed Web of Science ®Google Scholar
• Barnard EA, Skolnick P, Olsen RW, et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50(2):291-313
   PubMed Web of Science ®Google Scholar
• Butler SF, Benoit C, Budman SH, et al. Development and validation of an Opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006;3:5
   PubMedGoogle Scholar